TrialCancer immunology, immunotherapy : CII2014

Immunological response induced by abagovomab as a maintenance therapy in patients with epithelial ovarian cancer: relationship with survival-a substudy of the MIMOSA trial.

Alexia Buzzonetti et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.